ClinicalTrials.govpublic full text
Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment
graft versus host disease, graft-versus-host disease, ruxolitinib, mesenchymal stem cells, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 833782
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.